Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.90 Insider Own2.10% Shs Outstand33.65M Perf Week-9.71%
Market Cap1.98B Forward P/E- EPS next Y-7.44 Insider Trans-9.88% Shs Float25.67M Perf Month-37.27%
Income-344.70M PEG- EPS next Q-2.96 Inst Own80.80% Short Float18.36% Perf Quarter-49.21%
Sales252.00M P/S7.84 EPS this Y-0.20% Inst Trans-0.06% Short Ratio7.96 Perf Half Y-9.67%
Book/sh1.57 P/B37.42 EPS next Y33.60% ROA-48.40% Target Price151.90 Perf Year-49.20%
Cash/sh19.40 P/C3.03 EPS next 5Y-8.89% ROE-455.80% 52W Range47.57 - 125.00 Perf YTD-52.59%
Dividend- P/FCF- EPS past 5Y4.40% ROI-53.50% 52W High-53.00% Beta1.77
Dividend %- Quick Ratio4.50 Sales past 5Y170.50% Gross Margin98.30% 52W Low23.50% ATR6.84
Employees583 Current Ratio4.50 Sales Q/Q34.10% Oper. Margin- RSI (14)39.34 Volatility6.94% 11.84%
OptionableYes Debt/Eq10.31 EPS Q/Q-1.00% Profit Margin- Rel Volume0.57 Prev Close60.18
ShortableYes LT Debt/Eq10.31 EarningsFeb 25 BMO Payout- Avg Volume592.46K Price58.75
Recom1.80 SMA20-9.86% SMA50-28.82% SMA200-28.18% Volume339,152 Change-2.38%
Apr-02-20Initiated Chardan Capital Markets Buy $145
Mar-05-20Resumed BofA/Merrill Neutral $111
Feb-26-20Upgrade Citigroup Neutral → Buy $140 → $125
Feb-21-20Upgrade SVB Leerink Underperform → Mkt Perform
Jan-02-20Downgrade Citigroup Buy → Neutral $85 → $140
Dec-02-19Initiated Canaccord Genuity Buy
Sep-04-19Upgrade Citigroup Neutral → Buy $106 → $85
Jun-25-19Initiated Stifel Hold $89
May-10-19Reiterated B. Riley FBR Buy $169 → $158
May-03-19Upgrade Wells Fargo Market Perform → Outperform
Mar-01-19Upgrade RBC Capital Mkts Sector Perform → Outperform $130
Feb-22-19Downgrade SVB Leerink Mkt Perform → Underperform $70
Feb-15-19Reiterated BofA/Merrill Underperform $68 → $79
Feb-04-19Upgrade Raymond James Outperform → Strong Buy $184
Jan-31-19Initiated Credit Suisse Outperform $167
Jan-30-19Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jan-23-19Initiated UBS Buy $130
Jan-14-19Upgrade Laidlaw Hold → Buy $130
Dec-12-18Initiated B. Riley FBR Buy $155
Nov-19-18Upgrade Oppenheimer Perform → Outperform
Apr-01-20 09:04AM  Is Intercept (ICPT) Stock a Solid Choice Right Now? Zacks -7.24%
Mar-30-20 06:06PM  FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com
Mar-29-20 11:49AM  Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic MarketWatch
Mar-28-20 09:23PM  Hedge Funds Have Never Been This Bullish On Intercept Pharmaceuticals Inc (ICPT) Insider Monkey
Mar-26-20 04:24PM  After Crashing 33% In March, This Biotech Just Popped Here's Why Investor's Business Daily +9.18%
11:30AM  Why Is Intercept (ICPT) Down 30.9% Since Last Earnings Report? Zacks
08:00AM  Intercept Pharmaceuticals Provides Regulatory and Business Update GlobeNewswire
Mar-10-20 03:16PM  Coronavirus Is Bad and Good for Biotech Stocks Barrons.com
11:53AM  The Surprising Impact Coronavirus Will Have On Biotech Companies Investor's Business Daily
Mar-07-20 12:26AM  Edited Transcript of ICPT earnings conference call or presentation 25-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-20 08:00AM  Intercept to Present at the Cowen 40th Annual Health Care Conference GlobeNewswire +7.67%
Feb-27-20 08:32AM  Intercept Pharmaceuticals, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Feb-26-20 10:14AM  Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates Zacks +5.96%
Feb-25-20 08:25AM  Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.83%
07:00AM  Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update GlobeNewswire
06:30AM  Intercept Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-20 08:00AM  Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire
Feb-05-20 04:11PM  13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Feb-03-20 12:05PM  Is Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) CEO Salary Justified? Simply Wall St.
Jan-30-20 11:10AM  Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-29-20 08:00AM  Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH GlobeNewswire
Jan-10-20 11:51AM  3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
Jan-08-20 08:00AM  Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-20 12:40PM  Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In Benzinga
09:08AM  Intercept Pharma Has a New Liver Drug. Dont Expect FDA Approval to Lift the Stock, Analyst Says. Barrons.com
08:34AM  Analysts Expect Breakeven For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Simply Wall St.
Dec-26-19 05:00AM  Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical. Barrons.com
Dec-24-19 11:05AM  Why the 2020 NASH Revolution Could Prove Underwhelming GuruFocus.com
Dec-17-19 10:31AM  Gilead (GILD) Announces Top-Line Results From NASH Study Zacks
Dec-13-19 08:00AM  Intercept Provides Regulatory Update GlobeNewswire
Dec-10-19 03:36PM  Genfit Hopes to Buck the Odds With NASH Drug GuruFocus.com
08:00AM  Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York GlobeNewswire
Dec-05-19 07:00PM  Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet GlobeNewswire
11:31AM  Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 04:50AM  Is Intercept Pharmaceuticals (NASDAQ:ICPT) Using Debt In A Risky Way? Simply Wall St.
Dec-02-19 09:04AM  Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space Zacks
08:00AM  Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer GlobeNewswire
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
10:29AM  These 3 Biotech Stocks Could More Than Double in 2020, Says Wedbush TipRanks
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks +7.56%
Nov-26-19 11:07AM  Company News For Nov 26, 2019 Zacks +5.35%
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 04:20PM  This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test Investor's Business Daily +8.38%
08:00AM  FDA Accepts Intercepts NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review GlobeNewswire
Nov-22-19 02:27AM  Edited Transcript of ICPT earnings conference call or presentation 5-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-19 07:00AM  New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH GlobeNewswire
Nov-06-19 10:34AM  Intercept (ICPT) Earnings and Sales Miss Estimates in Q3 Zacks +6.24%
Nov-05-19 08:35AM  Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM  Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-29-19 08:00AM  Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
Oct-28-19 08:00AM  Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019 GlobeNewswire
Oct-23-19 02:14PM  Hedge Funds Have Never Been This Bullish On Intercept Pharmaceuticals Inc (ICPT) Insider Monkey
10:34AM  Analysts Estimate Intercept Pharmaceuticals (ICPT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-19 10:19AM  Does Market Volatility Impact Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price? Simply Wall St.
Oct-18-19 11:22AM  New Gilead CFO: Let's Make a Deal GuruFocus.com
Oct-11-19 05:10PM  Startup with eye on fatty liver disease NASH lays out $70M IPO plan American City Business Journals
Sep-27-19 04:05PM  Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH GlobeNewswire
Sep-26-19 04:16PM  This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years Investor's Business Daily
11:40AM  Enanta's Stock Down Despite NASH Drug Meeting Goal in Study Zacks
Sep-25-19 08:00AM  Intercept to Present at Upcoming Investor Conference in October GlobeNewswire
Sep-13-19 09:47AM  Who Has Been Selling Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares? Simply Wall St.
Sep-11-19 08:00AM  Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH GlobeNewswire
Sep-09-19 10:00AM  Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics Motley Fool
08:00AM  Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations GlobeNewswire
Sep-06-19 09:31AM  Why Is Intercept (ICPT) Down 2.5% Since Last Earnings Report? Zacks
Aug-26-19 12:00AM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
Aug-23-19 08:00AM  Intercept to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-19-19 02:45PM  Obesity Epidemic Leads To A New Problem And It Could Be Worth Billions Investor's Business Daily
Aug-12-19 07:28PM  Edited Transcript of ICPT earnings conference call or presentation 7-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 09:26AM  Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks +7.38%
05:59AM  Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79% Simply Wall St.
Aug-07-19 09:23PM  Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript Motley Fool
03:00PM  What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update Motley Fool
08:25AM  Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM  Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-31-19 08:00AM  Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019 GlobeNewswire
Jul-25-19 10:33AM  Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-24-19 06:00AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-16-19 10:28AM  4 Strong Buy Biotechs With Big 3Q19 Catalysts TipRanks
Jun-30-19 02:00PM  Better Buy: Intercept Pharmaceuticals vs. CV Sciences Motley Fool
Jun-21-19 01:42PM  An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued Simply Wall St.
Jun-17-19 01:50PM  ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention Benzinga +5.75%
Jun-13-19 09:06PM  Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy? Insider Monkey
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
Jun-11-19 08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
Jun-07-19 09:30AM  Why Is Intercept (ICPT) Down 5.2% Since Last Earnings Report? Zacks
Jun-06-19 04:33PM  Biotech Stocks Tumble As FDA Doubts Method Of Testing Drugs Investor's Business Daily -5.74%
11:44AM  ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study Benzinga
May-30-19 01:25PM  7 Stocks to Buy for Monster Growth InvestorPlace
07:00AM  Intercept to Present at Upcoming Investor Conferences in June GlobeNewswire
May-23-19 10:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-19-19 09:00AM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
May-16-19 06:11AM  Edited Transcript of ICPT earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-10-19 04:05PM  Intercept to Present at Upcoming Investor Conferences in May GlobeNewswire
May-09-19 02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
09:00AM  2 Reasons Intercept Pharmaceuticals Stock Tanked in April Motley Fool
07:56AM  The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut Benzinga
May-08-19 04:05PM  Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026 GlobeNewswire
03:00PM  What You Need to Know About Intercept Pharmaceuticals' Great Q1 Performance Motley Fool
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weyer ChristianEVP, Research & DevelopmentFeb 27Sale87.621139,90117,367Feb 28 07:00 PM
Weyer ChristianEVP, Research & DevelopmentJan 27Sale94.0472367,99117,837Jan 27 07:01 PM
Campagna JasonChief Medical OfficerJan 07Sale113.0273282,7316,303Jan 08 07:00 PM
Pruzanski MarkPresident & CEODec 31Option Exercise21.501002,150469,226Jan 03 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 31Option Exercise54.6326214,31318,984Jan 03 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 31Sale125.0026232,75018,722Jan 03 07:00 PM
Pruzanski MarkPresident & CEODec 31Sale125.0010012,500469,126Jan 03 07:00 PM
Weyer ChristianEVP, Research & DevelopmentDec 27Option Exercise59.0847027,76615,759Dec 30 07:01 PM
Weyer ChristianEVP, Research & DevelopmentDec 27Sale123.241,581194,84214,178Dec 30 07:01 PM
Pruzanski MarkPresident & CEODec 26Option Exercise21.504178,966469,543Dec 30 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 26Option Exercise54.63542,95018,776Dec 30 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 26Sale125.00546,75018,722Dec 30 07:00 PM
Pruzanski MarkPresident & CEODec 26Sale125.0041752,125469,126Dec 30 07:00 PM
Campagna JasonChief Medical OfficerDec 19Sale119.4515418,3957,444Dec 20 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 03Option Exercise54.63804,37018,722Dec 05 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Option Exercise59.1092754,78416,686Dec 02 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Sale101.651,040105,71615,646Dec 02 07:00 PM
Pruzanski MarkPresident & CEONov 26Option Exercise14.3035,437506,769504,563Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Option Exercise59.114,373258,49120,132Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Sale100.004,373437,30015,759Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 26Sale100.0035,4373,543,700469,126Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Option Exercise8.6714,563126,213483,689Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Option Exercise59.101,855109,62817,614Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Sale100.001,855185,50015,759Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Sale100.0014,5631,456,300469,126Nov 27 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Option Exercise53.418,325444,63834,043Nov 19 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Sale85.0012,1541,033,09021,889Nov 19 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 19Sale85.001,550131,75015,759Nov 19 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Option Exercise53.4150026,70526,929Nov 15 07:02 PM
Weyer ChristianEVP, Research & DevelopmentNov 13Sale85.0094680,41017,309Nov 15 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Sale85.0050042,50026,429Nov 15 07:02 PM
Bright LisaPresident, InternationalOct 29Sale75.0059544,62518,732Oct 31 07:00 PM
Ford David AChief Human Resources OfficerOct 23Sale70.00584,06011,396Oct 25 07:00 PM
Ford David AChief Human Resources OfficerSep 16Sale70.0080056,00011,546Sep 18 07:00 PM
AKKARAJU SRINIVASDirectorAug 28Buy60.325,207314,086403,688Aug 30 02:32 PM
Bright LisaPresident, InternationalJul 03Sale78.6659546,80319,857Jul 03 05:00 PM
Fundaro PaoloDirectorMay 20Option Exercise15.246,749102,88717,863May 22 07:00 PM
Benatti LucaDirectorMay 14Buy83.501,200100,2007,556May 14 07:00 PM
Shapiro DavidChief Medical OfficerMay 01Option Exercise31.902,00063,80041,499May 03 07:00 PM
Shapiro DavidChief Medical OfficerMay 01Sale86.282,000172,56039,499May 03 07:00 PM
AKKARAJU SRINIVASDirectorApr 25Option Exercise24.473,50085,66019,956Apr 29 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVApr 18Option Exercise54.631,75095,60319,599Apr 22 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Option Exercise31.902,00063,80041,499Apr 16 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Sale95.002,000190,00039,499Apr 16 07:01 PM